Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.78 |
| ▸ | CCR3 | P51677 | 4/20 | 0.76 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.74 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432094 | 0.85 | CHRM4 (1.00) | SLC6A2SLC6A4CCR3CHRM4 | |
| SCHEMBL17194340 | 0.85 | OPRM1 (0.66) | SLC6A2SLC6A4CCR3CHRM4MEN1 | |
| SCHEMBL18507035 | 0.85 | CHRM4 (0.65) | SLC6A2SLC6A4CCR3CHRM4TMEM97 | |
| SCHEMBL18507033 | 0.84 | MCHR2 (0.75) | SLC6A2SLC6A4CHRM4HTTSMN1; SMN2 | |
| SCHEMBL17194187 | 0.84 | CHRM4 (0.64) | SLC6A2SLC6A4CCR3CHRM4TMEM97 | |
| SCHEMBL17194307 | 0.84 | CHRM4 (0.64) | SLC6A2SLC6A4CCR3CHRM4TMEM97 | |
| SCHEMBL14430677 | 0.83 | CHRM4 (0.62) | CHRM4SMN1; SMN2 | |
| SCHEMBL17194299 | 0.83 | CHRM4 (0.63) | SLC6A2SLC6A4CCR3CHRM4TMEM97 | |
| SCHEMBL17194188 | 0.83 | L3MBTL3 (0.67) | SLC6A2SLC6A4CCR3CHRM4TMEM97 | |
| SCHEMBL18502056 | 0.83 | CHRM4 (0.63) | SLC6A2SLC6A4CCR3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131890-B1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | PASTEUR INSTITUT KOREA (KR) | 2019-04-24 | — | — | EP | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | SLC6A2 3168/4885SLC6A4 3863/4885CCR3 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.